SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target https://t.co/i7cnEfQNk6
Great piece highlighting AHR (exploited in trials of Zika and Influenza A) as a driver of hypersecretion of lung mucins with SARS-CoV-2 infection in respiratory failure: https://t.co/LZRIjVH4th #covid19 #SARSCoV2 #AHR #therapuetics #covid #research
Un article dans Nature décrit une piste thérapeutique pour les atteintes pulmonaires de la covid, qui consiste à cibler par un antagoniste (CH223191) le récepteur d'aryl hydrocarbone (AhR), perçu comme facteur pro-viral. 1/2 https://t.co/hKz0H6i26D
RT @ABsteward: ✨Interesting✨ SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target. #COVID19 #idtwitter https://t.co/zU…
RT @ABsteward: ✨Interesting✨ SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target. #COVID19 #idtwitter https://t.co/zU…
RT @ABsteward: ✨Interesting✨ SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target. #COVID19 #idtwitter https://t.co/zU…
RT @ABsteward: ✨Interesting✨ SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target. #COVID19 #idtwitter https://t.co/zU…
✨Interesting✨ SARS-CoV-2-induced lung pathology: AHR as a candidate therapeutic target. #COVID19 #idtwitter https://t.co/zUaYpPDV5W https://t.co/dMeKyu47ua